In 2008, Evan Unger acquired rights to a contrasting agent approved for use in Europe, dodecafluoropentane emulsion (DDFPe).
It was never marketed for competitive reasons, the story goes, but Unger saw potential beyond imaging. So after negotiating rights, he launched his third startup, NuvOx Pharma, with an aim to treat various forms of hypoxia (oxygen deficiency).
It was a good idea, according to judges of the Pitch Perfect competition at the MedCity INVEST conference in May. Unger’s pitch took first place in the biopharma track.
Read full article here
